Vaccine study for treating multiple common skin warts
Part of Infections, Skin clinical trials.
This Phase 2 study tests giving a Candida antigen plus a bivalent HPV vaccine to help shrink or clear multiple common skin warts. It may help people with warts on different body areas, with different sizes or how long they’ve had them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple common warts on your skin, potentially in more than one area
- Your warts can be different sizes and can have been present for any length of time
- You can still join whether your warts are considered “recalcitrant” (hard to treat) or not
- You must not be pregnant
- You must not have a history of an allergy (hypersensitivity) to Candida antigen or the bivalent HPV vaccine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an HPV vaccine can help shrink or clear cutaneous (skin) warts that have not responded to prior treatments. Participants get the study vaccine or a placebo to compare results and safety.
This trial tests a medication called cantharidin for treating common warts. It is for people age 2 and older who are generally healthy and have at least one common wart on the body (but not on palms, soles, face, or genitals). Participants cannot use other wart treatments during the study.
This trial tests a medicated liquid called cantharidin for treating common warts on the body (not on the face, soles, or private areas). The liquid is painted on by a doctor and later removed, and the goal is to see if it clears warts safely.
This study tests two different injected treatments for plantar warts (warts on the soles of your feet) to see which works better. If you have multiple plantar warts, you might be able to join.
This trial studies 2LPAPI® to see if it helps the body clear high-risk HPV infections in the cervix. It may be an option if you have a current HPV infection with mild/early abnormal cervical findings and can complete follow-up for about a year.
This study follows people who completed an earlier cantharidin trial to see how safe and effective the medicine is over a longer time. You may join if you still have treatable warts or finished the earlier study.
Hear when a new Warts trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.